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ABSTRACT
This study aimed to characterise Neisseria menin-
gitidis C:2b:P1.2,5 isolates from Poland, which
have now become predominant among serogroup
C isolates in this country. Overall, 44 isolates (25
invasive and 19 from contact carriers) were typed
by whole-cell ELISA and pulsed-ﬁeld gel electro-
phoresis. Additionally, the invasive isolates were
analysed by multilocus sequence typing, which
revealed that they all belonged to the ST-8
complex ⁄ cluster A4. The emergence of this clone
in other countries has resulted in mass immuni-
sation campaigns and has been associated with a
higher level of decreased susceptibility to peni-
cillin; however the present study detected only
one isolate that was penicillin-non-susceptible.
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Based on notiﬁcation data, the annual incidence of
invasive meningococcal disease (IMD) in Poland
in 2004 was 0.54 ⁄ 100 000 inhabitants, with
serogroup B predominating (http://www.pzh.
gov.pl/epimeld; unpublished data from the
National Reference Centre for Bacterial Menin-
gitis (NRCBM), Warsaw, Poland). However, since
2003, the NRCBM has recorded an increasing
number of cases of IMD caused by meningococci
of phenotype C:2b:P1.2,5, which now predomin-
ate among serogroup C isolates in Poland.
Although meningococci of the C:2b:P1.2,5 pheno-
type have been associated only with sporadic
cases in some countries, this phenotype has
become epidemic in other countries [1–4]. The
aim of the present study was to characterise
meningococcal isolates of phenotype C:2b:P1.2,5
from Poland.
The study was performed with 44 Neisseria
meningitidis isolates of C:2b (25 from IMD and 19
from contact carriers) and two invasive B:2b
isolates, all collected by the Polish NRCBM since
1997. Swabbing of close contacts of patients with
IMD was performed, with identiﬁcation of
asymptomatic carriers for ten of the IMD cases.
In two additional cases, contact carriers were
found despite negative culture results from the
corresponding IMD patient. Serotyping by whole-
cell ELISA and sequencing of the porA variable
regions were performed as described previ-
ously [5,6]. MICs of penicillin G (Sigma-Aldrich
Chemie, Steinheim, Germany) were determined
by agar dilution according to CLSI guidelines [7].
The relatedness among isolates was evaluated by
pulsed-ﬁeld gel electrophoresis (PFGE) of chromo-
somal DNA digested with SpeI (MBI Fermentas,
Vilinius, Lithuania) and by multilocus sequence
typing (MLST) [8–10] (http://pubmlst.org/
neisseria).
The distribution of invasive isolates of C:2b in
Poland over time is shown in Fig. 1. Epidemio-
logical links among cases caused by C:2b men-
ingococci were not established. One case of
septicaemia in a patient aged 51 years had a fatal
outcome (Table 1). Sequencing of porA revealed
that all isolates of C:2b:P1.2,5 possessed the P1.5,2
sequence variant, whereas the isolate of
C:2b:P1.16 possessed P1.21,16 (http://neisse-
ria.org/nm/typing/pora). All isolates respon-
sible for IMD, except for one with an MIC of
0.5 mg ⁄L, were susceptible to penicillin. PFGE
analysis revealed four different PFGE types
among invasive meningococci: type A, with three
subtypes, A1 (20 isolates), A2 (1) and A3 (1); type
B (1); type C (1); and type D (1). Three types were
found among isolates from carriers: type A, with
two subtypes, A1 (15) and A4 (1); type B (2); and
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type D (1). Types A and D may be possibly
related, based on a difference of four PFGE bands
[9]. MLST analysis classiﬁed all but one of the
invasive isolates as sequence type (ST)-8 (allelic
proﬁle: 2-3-7-2-8-5-2). The exception was the ﬁrst
isolate of C:2b:P1.2,5 identiﬁed in Poland, which
belonged to ST-66, which is a single variant locus
of ST-8 in fumC [11], and both of these STs belong
to the ST-8 complex ⁄ cluster A4. Analysis of two
invasive isolates of B:2b:P1.2,5 and B:2b:P1.5
recovered in 1998 and 2002, respectively, revealed
that they differed from C:2b isolates according to
both PFGE proﬁle and MLST type, with the allelic
proﬁles, 7-*-10-19-10-1-345 (* indicates that the adk
locus has been sequenced ﬁve times without
success) and 12-17-26-34-24-34-28 (new ST-4968),
respectively. The characteristics of the invasive
C:2b isolates are summarised in Table 1.
All meningococci of C:2b responsible for IMD
in Poland belonged to the ST-8 complex ⁄ cluster
A4, which is one of the two hyper-virulent
lineages responsible for most cases of serogroup
C infection worldwide [3]. For example, the
proportion of C:2b:P1.2,5 isolates among group
C meningococci in Spain increased from 4.6% in
1993 to 65% in 1996, and resulted in a mass
immunisation campaign against serogroup C
meningococci [1]. Although the present study
observed the rapid and seemingly efﬁcient dis-
semination of this clone, it has been associated,
thus far, with a relatively low case fatality rate
(4%) in comparison with the general mortality
rate from IMD [12]. A noticeable rise in the
occurrence of C:2b:P1.2,5 and C:2b:P1.5 meningo-
cocci has also been observed in Portugal and Italy,
Table 1. Demographical data for patients and typing results of Neisseria meningitidis C:2b isolates responsible for invasive
meningococcal disease in Poland, 1997–2005
No. Onset
Age
(years) Gender Diagnosis Region Phenotype porA type PFGE type ST ST complex
1 05.06.01 5 Male Meningitis Malopolska C:2b:P1.2,5 P1.5,2 B 66 ST-8 ⁄ cluster A4
2 03.09.02 16 Female Meningitis West Pomerania C:2b:P1.2,5 P1.5,2 A1 8 ST-8 ⁄ cluster A4
3 06.12.02 7 Female Meningitis West Pomerania C:2b:P1.2,5 P1.5,2 A1 8 ST-8 ⁄ cluster A4
4 12.03.03 17 Male Meningitis Holy Cross C:2b:P1.2,5 P1.5,2 A1 8 ST-8 ⁄ cluster A4
5 30.05.03 2 Female Meningitis Malopolska C:2b:P1.2,5 P1.5,2 Ca 8 ST-8 ⁄ cluster A4
6 22.07.03 9 Male Septicaemia Mazovia C:2b:P1.2,5 P1.5,2 A1 8 ST-8 ⁄ cluster A4
7 30.09.03 16 Female Meningitis Pomerania C:2b:P1.2,5 P1.5,2 A1 8 ST-8 ⁄ cluster A4
8 07.12.03 6 Male Meningitis Kujawsko-Pomorskie C:2b:P1.2,5 P1.5,2 A1 8 ST-8 ⁄ cluster A4
9 25.12.03 3 Female Meningitis West Pomerania C:2b:P1.2,5 P1.5,2 A1 8 ST-8 ⁄ cluster A4
10 29.12.03 12 Female Meningitis Malopolska C:2b:P1.2 P1.5,2 A1 8 ST-8 ⁄ cluster A4
11 02.01.04 43 Female Meningitis West Pomerania C:2b:P1.2,5 P1.5,2 A2 8 ST-8 ⁄ cluster A4
12 07.01.04 16 Female Septicaemia West Pomerania C:2b:P1.2,5 P1.5,2 A1 8 ST-8 ⁄ cluster A4
13 02.02.04 16 Male Meningitis West Pomerania C:2b:P1.2,5 P1.5,2 A1 8 ST-8 ⁄ cluster A4
14 12.02.04 4 Male Meningitis Pomerania C:2b:P1.2,5 P1.5,2 A1 8 ST-8 ⁄ cluster A4
15 10.03.04 16 Female Septicaemia Pomerania C:2b:P1.2,5 P1.5,2 A1 8 ST-8 ⁄ cluster A4
16 01.03.04 3 Male Septicaemia West Pomerania C:2b:P1.2,5 P1.5,2 A1 8 ST-8 ⁄ cluster A4
17 09.03.04 2 Male Septicaemia West Pomerania C:2b:P1.16 P1.21,16 A1 8 ST-8 ⁄ cluster A4
18 04.04.04 3 Female Meningitis Kujawsko-Pomorskie C:2b:P1.2,5 P1.5,2 A3 8 ST-8 ⁄ cluster A4
19 07.05.04 3 months Male Meningitis Silesia C:2b:P1.2,5 P1.5,2 A1 8 ST-8 ⁄ cluster A4
20 03.09.04 19 Female Meningitis West Pomerania C:2b:P1.2,5 P1.5,2 D 8 ST-8 ⁄ cluster A4
21 02.11.04 3 Male Meningitis West Pomerania C:2b:P1.2,5 P1.5,2 A1 8 ST-8 ⁄ cluster A4
22 18.11.04 51 Female Septicaemiab West Pomerania C:2b:P1.2,5 P1.5,2 A1 8 ST-8 ⁄ cluster A4
23 23.03.05 6 Female Meningitis ⁄ septicaemia Mazovia C:2b:P1.2,5 P1.5,2 A1 8 ST-8 ⁄ cluster A4
24 09.04.05 15 Female Meningitis ⁄ septicaemia Warminsko-Mazurskie C:2b:P1.2,5 P1.5,2 A1 8 ST-8 ⁄ cluster A4
25 06.04.05 2 Female Meningitis ⁄ septicaemia Warminsko-Mazurskie C:2b:P1.2,5 P1.5,2 A1 8 ST-8 ⁄ cluster A4
aIsolate non-susceptible to penicillin.
bSepticaemia with fatal outcome.
ST, sequence type.
Fig. 1. Map of Poland showing the distribution of invasive
Neisseria meningitidis C:2b isolates over time. Cases of
invasive meningococcal disease occurred in the years 2001
(m), 2002 (¯), 2003 (n), 2004 (d), and 2005 up to April (w).
W-P, West Pomerania; P, Pomerania; W-M, Warminsko-
Mazurskie; K-P, Kujawsko-Pomorskie; Maz, Mazovia; Sil,
Silesia; HC, Holy Cross; Mal, Malopolska.
1028 Clinical Microbiology and Infection, Volume 12 Number 10, October 2006
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 1021–1045
where 28% and 78%, respectively, of isolates
belonging to these phenotypes showed decreased
susceptibility to penicillin [2,3]. In a study in
France, 64% of C:2b:P1.2,5 isolates showed
decreased susceptibility to penicillin, and one
isolate had an unusually high penicillin MIC of
1.5 mg ⁄L [13]. This contrasts with the present
study, in which only one C:2b isolate was non-
susceptible to penicillin.
Two invasive isolates of B:2b from the collec-
tion of the NRCBM were analysed to determine
whether the phenomenon of capsule switching
in meningococci of cluster A4 had occurred.
This phenomenon has been described previ-
ously in Spain, where B:2b:P1.2,5 isolates of
cluster A4 were found not only after, but also
before, a mass immunisation campaign, showing
that such genetic variants may be produced
randomly in a meningococcal population, inde-
pendently of vaccination pressure [1]. In Poland,
where mass vaccination against serogroup C
meningococci has never been implemented,
capsule switching was not detected among the
isolates studied. However, an isolate was found
that had a different sero-subtype and porA
sequence, but was indistinguishable from iso-
lates of C:2b:P1.2,5 by both PFGE and MLST.
Epidemiological investigations should therefore
be cautious and sensitive to rapid changes
occurring in the meningococcal population.
An interesting ﬁnding of the present study was
the high number of meningococci isolated from
close contacts of IMD patients. Until recently,
meningococci of C:2bwere isolated primarily from
invasive disease, and only rarely from carriage in
the general population, even in areas with high
numbers of cases of IMD caused by C:2b:P1.2,5
isolates [4,14]. Although the contact carriage data
cannot be compared with general carriage studies,
the high number of asymptomatic carriers among
close contacts of IMD patients may act as a
reservoir for further transmission and spread
[15]. Extended population-based carriage studies
are necessary to investigate this hypothesis.
In view of the increasing prevalence of
C:2b:P1.2,5 meningococci in Poland, combined
with experience in other countries, it is clear that
there is a need for more vigilant epidemiological
surveillance of meningococci with this phenotype
in Poland. Mass vaccination may be required,
particularly in the regions most affected. Addi-
tionally, decreased susceptibility to penicillin has
been associated previously with this phenotype,
and any emergence of decreased penicillin
susceptibility in Poland will have an impact on
the empirical treatment of IMD, for which peni-
cillin has been the drug of choice to date.
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ABSTRACT
A 3-year retrospective study evaluated the effect-
iveness and safety of cefepime plus a ﬂuoroqui-
nolone for treating bone and joint infections
caused by Gram-negative bacilli (GNB) in 28
patients. Intra-operative cultures yielded primar-
ily Pseudomonas spp. and Enterobacter cloacae. Full
recovery (cure) was observed in 79% of patients.
There were no serious adverse effects and no
resistant organisms were isolated. The results of
the study conﬁrmed the safety and effectiveness
of cefepime combined with a ﬂuoroquinolone for
the treatment of bone and joint infections caused
by Gram-negative bacilli.
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Numerous therapeutic approaches to the treat-
ment of bone and joint infections caused by
Gram-negative bacilli (GNB) have been described
[1–6]. Several reports [7–10] have demonstrated
that ﬂuoroquinolones inhibit the adherence of
GNB to implanted devices. In addition, it has
been reported [7,10,11] that ﬂuoroquinolones
have activity against non-growing cells of Pseu-
domonas, and that they are able to eradicate
bioﬁlms in vitro [9]. Breilh et al. [12] reported that
cefepime diffuses readily into bone. The activity
of cefepime against GNB, including many dere-
pressed mutants [7,13], and the synergic activity
of new cefepime ⁄ﬂuoroquinolone combinations
against some GNB [13], makes cefepime an
interesting choice for the treatment of bone and
joint infections. This retrospective study evalu-
ated the safety and the efﬁcacy of cefepime ⁄ﬂuor-
oquinolone combinations for the treatment of
bone and joint infections. Results are reported
only for those patients who were followed for
more than 2 years.
During the 3-year period January 1999 to
December 2001, the medical charts of patients
treated by the Orthopaedic Surgery Service, Lille,
France, for bone and joint infections associated
with GNB were reviewed. Clinical criteria for
inclusion were fever >38C and inﬂammation in
the surgical area. Biological criteria included an
erythrocyte sedimentation rate >50 mm ⁄h and
elevated C-reactive protein (>10 mg ⁄L). Radiolo-
gical criteria were pseudarthrosis, a loosening
prosthesis or osteomyelitis. Antibiotics were dis-
continued 15–30 days before obtaining wound
cultures. In case of sepsis, samples were collected
immediately. At least three samples were taken
intra-operatively. Blood specimens were drawn
from all febrile patients. Superﬁcial samples were
not used. Plates incubated at 37C were examined
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